免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，春立医疗市值为86亿元。 每经头条（nbdtoutiao）——近120个品牌、1600辆车逐鹿西南！下半年国内首个A级车展开幕：新能 源"第三极"将改写车市格局 （记者 王可然） 每经AI快讯，春立医疗（SH 688236，收盘价：22.35元）8月29日晚间发布半年度业绩报告称，2025年 上半年营业收入约4.88亿元，同比增加28.27%；归属于上市公司股东的净利润约1.14亿元，同比增加 44.85%；基本每股收益0.3元，同比增加42.86%。 ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-037 北京市春立正达医疗器械股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》、《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》的相关规定，北京市 春立正达医疗器械股份有限公司（以下简称"本公司"或"公司"）董事会对 2025 年半年度募集资金存放与实际使用情况作如下报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经上海证券交易所科创板股票上市委员会审核同意，并根据中国证券监督管 理委员会出具证监许可〔2021〕3702 号同意注册的文件，公司获准向社会公众 公开发行人民币普通股（A 股）股票 38,428,000 股，每股面值人民币 1.00 元， 发行价格为每股人民币 29.81 元，共计募集资金人民币 114,553.87 万元。扣除发 行费用（不含增值税）后，募集资金净额为 106,712. ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-038 北京市春立正达医疗器械股份有限公司 关于使用部分闲置募集资金和自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日分别召开了第五届董事会第二十六次会议、第五届监事会第十八次会议，会议审议 通过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司在 不影响公司募集资金投资项目（以下简称"募投项目"）正常实施并保证募集资金安 全的前提下，使用最高不超过 7 亿元（含 7 亿元）的部分闲置募集资金及最高不超过 14 亿元（含 14 亿元）的自有资金进行现金管理。在上述额度内，资金可以滚动使用， 使用期限自董事会审议通过之日起 12 个月内有效。 具体情况如下： 单位：人民币元 董事会授权公司管理层在授权额度和期限内行使现金管理投资决策权并签署相关 合同文件。上述事项在公司董事会审批权限范围内，无需提交公司股东会审批。公司 监事会发表 ...

北京市春立正达医疗器械股份有限公司 2025 年度提质增效重回报专项行动方案的 固定板系统等产品注册证。上述脊柱产品注册证的取得完善了公司脊柱系列产品线，进 一步提高公司在脊柱骨科行业的市场竞争力。 运动医学领域，公司取得了聚醚醚酮敲入式免打结锚钉、可调节带袢钛板、聚醚醚 酮带线锚钉等产品注册证，进一步丰富了公司运动医学产品线，公司在运动医学领域的 布局更加完善，齐备的运动医学产品线利于临床的选用。 创伤领域，公司在积极研发创伤业务领域的产品。截至 2025 年 6 月 30 日，公司创 伤系列产品已有多款产品获批上市，包括接骨板、髓内钉、外固定支架、金属骨针、空 心接骨螺钉、钛网板系统等，进一步补充了公司的骨科业务产品线。 半年度评估报告 为践行以"投资者为本"的上市公司发展理念，维护公司全体股东的利益，基于对 经营状况和未来发展前景的信心，围绕立足主业、提升科技创新水平、回报股东、加强 投资者沟通等方面，北京市春立正达医疗器械股份公司（以下简称"公司"或"春立医 疗"）于 2025 年 5 月 28 日发布了《2025 年度"提质增效重回报"专项行动方案》（以 下简称"行动方案"），以进一步优化经营效率、 ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-039 北京市春立正达医疗器械股份有限公司 关于计提 2025 年半年度资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日召开第五届董事会第二十六次会议、第五届监事会第十八次会议，审议 通过了《关于计提 2025 年半年度资产减值准备的议案》。 现将相关具体情况公告如下： 一、计提减值准备的情况概述 对于其他应收款，本公司则根据款项的性质，将其划分为具有不同信用风险 特征的组合，再针对每个组合，综合考虑各类款项的回收风险特点、历史回收情 况等因素，在组合基础上计算相应的预期信用损失。 2025 年半年度，公司以预期信用损失为基础，对应收账款、其他应收款进行 减值测试，计提信用减值损失 12,418,491.12 元。 （二）资产减值损失 资产负债表日，存货按照成本与可变现净值孰低计量，当期可变现净值低于 成本时，提取存货跌价准备，并按单个存货项目计提存货跌 ...

Core Viewpoint - The stock of Chunli Medical (688236) has experienced a decline, with a closing price of 21.92 yuan on August 27, 2025, down by 2.97% [1] Group 1: Stock Performance and Trading Data - On August 27, 2025, the stock had a turnover rate of 0.82%, with a trading volume of 23,600 lots and a transaction amount of 53.18 million yuan [1] - The net outflow of main funds was 2.87 million yuan, accounting for 5.4% of the total transaction amount, while retail investors saw a net inflow of 2.20 million yuan, representing 4.13% of the total [1][2] - Over the past five days, the stock has seen fluctuations in fund flows, with significant net inflows and outflows from different investor categories [2] Group 2: Financial Metrics and Industry Comparison - Chunli Medical's total market value is 8.408 billion yuan, which is below the industry average of 12.081 billion yuan, ranking 45th out of 123 in the medical device sector [3] - The company reported a net profit of 58.07 million yuan for the first quarter of 2025, reflecting a year-on-year increase of 5.2%, with a gross margin of 66.69% [3] - The company's price-to-earnings ratio (P/E) stands at 36.2, significantly lower than the industry average of 72.56, ranking 43rd out of 123 [3] Group 3: Analyst Ratings - In the last 90 days, two institutions have issued buy ratings for Chunli Medical, indicating positive sentiment among analysts [4]

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Spring Medical, indicating a slight decline in stock price and notable financing activities on August 26 [1] - On August 26, Spring Medical's stock price decreased by 0.70%, with a trading volume of 51.21 million yuan, and a net financing purchase of 2.68 million yuan [1] - As of August 26, the total balance of margin trading for Spring Medical was 43.59 million yuan, which accounts for 0.67% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products being joint prosthetics and spinal implants [2] - The company reported a revenue of 230 million yuan for the first quarter of 2025, reflecting a year-on-year growth of 3.60%, and a net profit attributable to shareholders of 58.07 million yuan, up by 5.20% [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Group 3 - As of March 31, 2025, the number of shareholders for Spring Medical increased by 7.48% to 7,182, while the average circulating shares per person decreased by 6.99% to 11,063 shares [2] - Among the top ten circulating shareholders, Zhonggeng Small Cap Value Stock holds 2.87 million shares, remaining unchanged, while Hong Kong Central Clearing Limited increased its holdings by 1.11 million shares to 2.29 million shares [3] - New shareholders include Ping An Low Carbon Economy Mixed A, which holds 1 million shares, while some funds exited the top ten circulating shareholders list [3]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a slight increase, with a closing price of 22.75 yuan on August 25, 2025, reflecting a 0.35% rise, while the overall market sentiment indicates mixed fund flows [1][2]. Fund Flow Summary - On August 25, 2025, the net outflow of main funds was 435.19 million yuan, accounting for 7.46% of the total transaction amount, while retail investors saw a net inflow of 481.9 million yuan, representing 8.27% of the total [1][2]. - Over the past five days, the fund flow data shows fluctuations, with significant net outflows from main funds on August 22 (2008.72 million yuan) and August 21 (252.93 million yuan), while retail investors had notable inflows on those days [2]. Company Performance Metrics - Chunli Medical's total market value is 8.726 billion yuan, with a net asset value of 2.879 billion yuan and a net profit of 58.071 million yuan, ranking 45th, 52nd, and 42nd respectively in the medical device industry [3]. - The company reported a gross margin of 66.69% and a net margin of 25.25%, both of which are significantly higher than the industry averages of 51.33% and 10.71% respectively [3]. - In the first quarter of 2025, the company's main revenue was 230 million yuan, showing a year-on-year increase of 3.6%, while the net profit increased by 5.2% [3]. Industry Ratings - In the last 90 days, three institutions have issued buy ratings for Chunli Medical, indicating positive sentiment towards the stock [4].

公司公告汇总 春立医疗（证券代码：688236）将于2025年9月1日（星期一）上午10:00-11:00举行2025年半年度业绩说 明会。会议将在上海证券交易所上证路演中心以网络互动形式召开。公司计划在2025年8月30日发布 2025年半年度报告，为让投资者更全面深入地了解公司经营成果和财务状况，将针对2025年半年度的经 营成果及财务指标与投资者进行互动交流。出席人员包括董事长史文玲女士、总经理史春生先生、财务 总监卢宏悦女士和董事会秘书解凤宝先生。投资者可在2025年9月1日上午10:00-11:00通过互联网登录上 证路演中心在线参与，也可在2025年8月25日至8月29日16:00前登录上证路演中心网站首页点击"提问预 征集"栏目或通过公司邮箱ir@clzd.com提问。联系人：公司证券部，电话：010-87321998，邮箱： ir@clzd.com。投资者可通过上证路演中心查看本次投资者说明会的召开情况及主要内容。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年8月22日收盘，春立医疗（688236） ...

Group 1 - The core point of the article highlights the financing activities of Chunli Medical, indicating a net sell-off in recent trading days [1] - On August 22, Chunli Medical had a financing buy-in amount of 0.15 billion, ranking 1288th in the market, with a financing repayment amount of 0.16 billion, resulting in a net sell-off of 0.8917 million [1] - Over the last three trading days (August 20-22), Chunli Medical recorded financing buy-ins of 0.13 billion, 0.07 billion, and 0.15 billion respectively [1] Group 2 - In terms of securities lending, on August 22, there were no shares sold or net sold in the securities lending market for Chunli Medical [1]